Tandem Diabetes Care (TNDM) Asset Writedowns and Impairment (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Asset Writedowns and Impairment data on file, last reported at $2.1 million in Q1 2026.

• Quarterly Asset Writedowns and Impairment rose 47.38% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (down 29.69% YoY) and the FY2025 annual result came in at $9.5 million, down 5.02% from the prior year.
• Asset Writedowns and Impairment declined to $2.1 million in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $12.7 million in Q2 2023 to a low of $346000.0 in Q1 2022.
• A 5-year average of $3.3 million and a median of $2.1 million in 2026 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment jumped 1011.28% — and 2024, when it tumbled 88.0%.
• Tracing TNDM's Asset Writedowns and Impairment over 5 years: stood at $7.6 million in 2022, then plunged by 82.71% to $1.3 million in 2023, then surged by 510.02% to $8.0 million in 2024, then tumbled by 65.15% to $2.8 million in 2025, then retreated by 24.16% to $2.1 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $2.1 million (Q1 2026), $2.8 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.